Pharmaron Beijing Co., Ltd.

Overview

Pharmaron Beijing Co., Ltd. is a leading pharmaceutical R&D service provider offering a range of drug discovery and development services across the entire pharmaceutical value chain. The company provides comprehensive laboratory and manufacturing services to support its clients in the development of innovative pharmaceuticals.

Therapeutic areas

API / Drug Master Files

Pharmaron Beijing Co., Ltd. holds 57 active (97 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• DARIDOREXANT HYDROCHLORIDE , NON STERILEActive2025-10-28
• TEDIZOLID PHOSPHATEActive2025-05-28
• SOTAGLIFLOZINActive2025-05-28
• TIRZEPATIDEActive2023-08-30
• DIFELIKEFALIN ACETATEActive2023-08-02
• TAURINEActive2023-01-12
• ISTRADEFYLLINEActive2022-10-29
• RISDIPLAMActive2022-04-07
• (-)-ACYLFULVENEActive2022-03-03
• SEMAGLUTIDEActive2021-04-22
• STIRIPENTOLActive2021-04-19
• EXENATIDEActive2020-12-15
• TEDUGLUTIDEActive2020-12-08
• PLECANATIDEActive2020-12-08
• IOPROMIDEActive2020-12-04

Showing 15 of 97 Drug Master Files.

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to Pharmaron Beijing Co., Ltd. in our records. PharmaTek screens the full directory against live FDA enforcement data.